India's Next Export Engine: The Medical Value Travel Opportunity
India treated more than 507,000 foreign patients in 2025, and the government projects the medical value travel sector to nearly double — from $8.7 billion to $16.2 billion — by 2030. Procedures that cost $150,000+ in the United States run $5,000–$8,500 in India at JCI-accredited hospitals. This report maps the market's actual size, prices out leading procedures against the US and UK, identifies which hospital groups are really leading, traces where patients come from, and makes the case that the single largest gap holding the sector back is the absence of a hospital built exclusively for the international patient.
Free Report
India's Next Export Engine: The Medical Value Travel Opportunity
No spam. Instant download.
Key Findings
- 1
India's medical value travel market is projected to nearly double, from $8.7 billion (2025) to $16.2 billion (2030) — independent research houses put the 2031 figure as high as $22.1 billion
- 2
More than 507,000 foreign nationals travelled to India specifically for medical treatment in 2025, out of 9.15 million total foreign tourist arrivals
- 3
A coronary bypass costs $5,000–$8,500 in India versus $150,000–$200,000 in the United States — a 90–96% saving that holds across procedures from joint replacement to liver transplant
- 4
Bangladesh alone supplies roughly two-thirds of India's medical-visa arrivals; bilateral partnerships with Maldives, Mauritius and Oman could be a template for larger African and CIS markets
- 5
India has only 57–61 JCI-accredited hospitals against a base of over 69,000 nationwide — real medical-tourism capacity is concentrated in a narrow, identifiable tier of institutions
- 6
No single Indian hospital or city yet functions as the unambiguous destination brand the way Bumrungrad does for Bangkok — India's leadership is real but fragmented across five or six credible hospital groups and four regional corridors
The Opportunity: Sizing India's Medical Value Travel Market
India's medical value travel market was valued at $8.7 billion in 2025 and is projected by the Ministry of Tourism to reach $16.2 billion by 2030. Independent research houses estimate the figure could reach $22.1 billion by 2031, depending on whether wellness and AYUSH tourism are counted alongside clinical medical travel. More than 507,000 foreign nationals received medical-visa approvals in 2025 — out of 9.15 million total foreign tourist arrivals — a figure that understates actual medical travel since many patients enter on tourist visas. The sector is growing on the back of three structural advantages: a 60–96% cost advantage over Western markets, a clinical workforce and accreditation base that few competing destinations can match at scale, and a Union Budget 2026-27 policy commitment to five Regional Medical Hubs that could anchor the next phase of capacity expansion.
The Price Advantage: What India Actually Costs, Procedure by Procedure
The cost advantage is the sector's most durable competitive moat. A coronary artery bypass graft runs $5,000–$8,500 in India at a JCI-accredited hospital, versus $150,000–$200,000 in the United States and $30,000–$45,000 in the UK private sector. A total knee replacement costs $6,000–$9,000 in India versus $35,000–$50,000 in the US. A liver transplant runs $25,000–$40,000 in India versus $300,000–$500,000 in the US. The saving is large enough that it typically covers the patient's flights, accommodation, and an attendant's stay — and still leaves a substantial net saving. This arithmetic holds across cardiac, orthopedic, oncology, and fertility procedures, which together account for the majority of medical-travel volumes.
The Hospital Landscape: Who Is Actually Leading
There is no single leader. Apollo Hospitals leads on geographic reach and brand recognition abroad, with dedicated international patient departments across 12 cities and a network of overseas representative offices. Medanta leads on complex multi-specialty cases — particularly liver transplant and cardiac surgery — where clinical outcomes are the primary decision driver. Fortis and Narayana Health lead on cost-competitiveness, with Narayana's Cayman Islands model demonstrating that Indian clinical teams can deliver world-class outcomes at a fraction of Western costs even outside India. Leadership is fragmented across five or six credible groups and four regional corridors: Delhi-NCR, Chennai and Tamil Nadu, Kochi and Kerala, and the fast-growing East and Northeast corridor anchored by Kolkata and Guwahati.
The Institutional Gap Behind the Opportunity
Every leading Indian hospital group markets an International Patient Department. None were built, staffed, priced and governed from the ground up as an institution whose primary patient is not Indian. That gap — not price, not clinical quality, not accreditation — is the largest remaining distance between India's medical-travel potential and its realised market share. Thailand's Bumrungrad and Singapore's flagship private hospitals were built around the international patient as the design brief, not an add-on service: dollar-denominated package pricing, country-desk staffing by language, and hospitality-grade extended-stay infrastructure built into the floor plan rather than added on. India's Union Budget 2026-27 proposal for five Regional Medical Hubs is the first policy vehicle capable of anchoring that kind of purpose-built facility — if hospital groups and investors treat it as a greenfield opportunity rather than an extension of an existing campus.
Research Methodology
This report synthesises government disclosures (Ministry of Tourism, PIB), independent market research (Mordor Intelligence, Future Market Insights, IMARC Group), medical-tourism cost-comparison data, and hospital-group public disclosures, current as of September 2026. Figures are triangulated across sources and presented as ranges where methodologies diverge — for instance, government market-size estimates versus independent research house projections differ depending on whether wellness and AYUSH tourism are counted alongside clinical medical travel. This is a secondary-research synthesis, not a primary fieldwork study.
Who Should Read This Report
Hospital chains and international-patient department leaders benchmarking their positioning against competitors; policymakers and tourism and health ministry stakeholders shaping medical-visa and infrastructure policy; healthcare investors and PE firms evaluating greenfield hospital opportunities; medical-tourism facilitators and cross-border insurers; and hospital architects and operators designing for the international-patient segment specifically.
Free Download
Get the full 17-page report
Primary research, data-backed findings, and strategic recommendations — all in one PDF. Free to download.
Frequently Asked Questions
What is the size of India's medical tourism market?
India's medical value travel market is projected by the government to grow from $8.7 billion in 2025 to $16.2 billion by 2030. Independent research houses estimate the market could reach $22.1 billion by 2031 or higher, depending on whether wellness and AYUSH tourism are included.
How much cheaper is treatment in India compared to the US or UK?
Typically 60–85% cheaper, and often more for high-ticket procedures. A coronary bypass runs $5,000–$8,500 in India versus $150,000–$200,000 in the US and $30,000–$45,000 in the UK private sector — a saving that usually still covers the patient's flights and an attendant's stay.
Which hospitals lead India's medical tourism sector?
There is no single leader. Apollo Hospitals leads on geographic reach and brand recognition abroad; Medanta leads on complex, multi-specialty cases like liver transplant; Fortis and Narayana Health lead on cost-competitiveness. Leadership is fragmented across five or six credible groups and four regional corridors: Delhi-NCR, Chennai/Tamil Nadu, Kochi/Kerala, and the fast-growing East/Northeast corridor.
Which countries send the most medical tourists to India?
Bangladesh is by far the largest source market, accounting for roughly two-thirds of India's 507,000+ medical-visa arrivals in 2025. Iraq, Uzbekistan, Somalia, Turkmenistan, Oman and Kenya round out the top source countries, spanning the Gulf, CIS and East Africa corridors.
Does India need a hospital built specifically for international patients?
Yes — this is the report's central argument. India's hospitals treat international patients well, but none were designed from the ground up around that patient the way Thailand's Bumrungrad or Singapore's Mount Elizabeth were: dollar-denominated package pricing, country-desk staffing by language, and hospitality-grade extended-stay infrastructure built into the floor plan rather than added on.
Related Reports
The Next Cancer Hospital: Where India's Oncology Infrastructure Gap Meets Investor Opportunity
Hospital Industry in India 2026: Bed Economics, Whitespace, and the Tier-2 Question
Private Equity in Indian Healthcare 2026: Deal Trends, Valuations, and What Exits Actually Look Like
Custom Research
Need custom research on this market?
Our published reports cover broad themes. For research specific to your geography, therapy area, or competitive situation, talk to InsightRx.